(Q43854731)

English

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials

scientific article published in January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

author name string

Lennart Estborn

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Svante Joelson

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

627-636

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

https://scigraph.springernature.com/pub.10.2165/00002018-200831070-00008

0 references

Does gastric acid suppression increase the risk of community-acquired pneumonia?

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200831070-00008

21 January 2018

One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A potential bias in safety evaluation during open-label extensions of randomized clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for a long duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Community-acquired pneumonia and use of gastric acid-suppressive drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acid suppression and pneumonia: a clinical indication for rational prescribing

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastric acid‐suppressive therapy and community‐acquired respiratory infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/18558796

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00002018-200831070-00008

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43854731&oldid=2103912408"